Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIFEDIPINE FIRST GENERIC APPROVAL GRANTED TO PUREPAC; EFFECTIVE DATE

Executive Summary

NIFEDIPINE FIRST GENERIC APPROVAL GRANTED TO PUREPAC; EFFECTIVE DATE of the ANDA approval, however, is delayed until an as-yet-undetermined date because of ANDA exclusivity that may be granted to another company. Purepac received approval for nifedipine 10 and 20 mg caps (Pfizer's Procardia and Miles' Adalat) on April 28. Under provisions of the Waxman/Hatch law, the first company to submit an ANDA for a generic drug and successfully challenge the innovator's patent is entitled to 180 days of marketing exclusivity, starting from either the date of its approval or the date of a court ruling of noninfringement. FDA explained in its approval letter to Purepac that an undisclosed generic firm submitted its nifedipine marketing application prior to Purepac and is currently in litigation with Pfizer over the validity of the nifedipine patent, which expires in January 1991. "Because of this litigation, the effective date of approval of your application must be delayed until a ruling by a court that the patent is invalid or will not be infringed, or the drug product which is the subject of this previously submitted application is the first commercially marketed, whichever is earlier," FDA told the generic company. The patent reportedly covers formulation of the drug. Purepac is also still in litigation with Pfizer over the nifedipine patent. Purepac's approval marks the second time that a generic firm has been delayed from entering the market by ANDA exclusivity provisions when the exclusivity holder had not yet received its ANDA approval. American Therapeutics received the first approval for a generic version of Lederle's Maxzide in November 1987, but was prevented from marketing because of an exclusivity grant to Vitarine. Vitarine subsequently received ANDA approval in December, starting off the 180-day exclusivity time clock.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel